Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Wierda, W. G., Zhao, W., Heerema, N. A., Luan, Y., Liu, E. A., Dean, J. P., O'Brien, S. M. AMER SOC HEMATOLOGY. 2018
View details for DOI 10.1182/blood-2018-99-110847
View details for Web of Science ID 000454842800284